Page last updated: 2024-12-07
n-hydroxythalidomide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
N-hydroxythalidomide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 124398 |
| CHEMBL ID | 365514 |
| SCHEMBL ID | 13364982 |
| MeSH ID | M0168209 |
Synonyms (16)
| Synonym |
|---|
| nsc-528759 |
| nsc528759 |
| n-hydroxythalidomide |
| 2-(1-hydroxy-2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
| CHEMBL365514 |
| unii-s99d86td4b |
| 1h-isoindole-1,3(2h)-dione, 2-(1-hydroxy-2,6-dioxo-3-piperidinyl)- |
| s99d86td4b , |
| 126663-38-5 |
| SCHEMBL13364982 |
| 1'-hydroxy thalidomide |
| 1'-hydroxythalidomide |
| 1'-hydroxy thalidomide, (+/-)- |
| DTXSID60925664 |
| 2-(1-hydroxy-2,6-dioxopiperidin-3-yl)-1h-isoindole-1,3(2h)-dione |
| Q27289078 |
Research Excerpts
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| " The purpose of this work was to evaluate the in vitro and in vivo immunosuppressive effects of Thd and its derivative, N-Hydroxythalidomide (H-Thd), alone and in combination with cyclosporin A (CsA), upon different in vitro lymphocyte activation pathways and in vivo local graft-versus-host-reaction (GvHR)." | ( In vitro and in vivo immunosuppressive potential of thalidomide and its derivative, N-hydroxythalidomide, alone and in combination with cyclosporin A. Chuong, PH; Claude, JR; Galons, H; Huynh-Thien, D; Righenzi, S; Voisin, J; Warnet, JM; Zhu, J, 1997) | 0.73 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (3)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID252970 | Percent cell proliferation of human leukemia cell line HL-60 at 1*E-5 M | 2005 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13 | Cell differentiation inducers derived from thalidomide. |
| AID252627 | NBT positivity against human leukemia cell line HL-60 at 1*E-5 M | 2005 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13 | Cell differentiation inducers derived from thalidomide. |
| AID340116 | Antagonist activity at progesterone receptor in human T47D cells assessed as inhibition of progesterone-induced alkaline phosphatase activity at 100 uM | 2008 | Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14 | Progesterone receptor antagonists with a 3-phenylquinazoline-2,4-dione/2-phenylisoquinoline-1,3-dione skeleton. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.56
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||